Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia With an IDH2 Mutation
NCT04203316Phase 2Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Aug 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of enasidenib in acute myeloid leukemia (AML), sponsored by Children's Oncology Group. Primary endpoints: Incidence of dose limiting toxicities at 28 days, Area under the plasma concentration versus time curve at 2 days and 3 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04203316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203316.